Home | Welcome to Contract Pharma   
Last Updated Friday, September 19 2014
Print RSS Feed

WuXi PharmaTech, PBI In Biomarker Alliance



By Kristin Brooks



Published March 11, 2014
Related Searches: biopharma companies bioanalysis Development Clinical Trial
WuXi PharmaTech and Pacific Biomarkers (PBI) have entered a collaboration under which PBI will provide access to its portfolio of validated biomarker assays to support WuXi's clinical trial testing services, including bioanalysis and central lab services for pharma and biopharma companies performing clinical trials in China.

PBI’s biomarkers include therapeutics areas of cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.

"We are very pleased to reach this agreement with Pacific Biomarkers, which broadens WuXi's biomarker capabilities in support of our clients' clinical development," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "Biomarkers are a new and important tool in the development of personalized medicines for many serious diseases."

"Partnering with WuXi enables us to realize considerable value in our biomarker assets," said Ronald Helm, chief executive officer of Pacific Biomarkers. "This agreement will allow us to support a broader spectrum of companies developing medicines in Asia with special emphasis on clinical trials performed in China."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On